FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Furman

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Procedures

Disorders

Myocardial Infarction

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Andrew L Frelinger; Joseph A Jakubowski; Youfu Li; Marc R Barnard; Matthew D Linden; I Tarnow; Marsha L Fox; Atsuhiro Sugidachi; Kenneth J Winters; Mark I Furman; Alan D Michelson
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Andrew L Frelinger; Joseph A Jakubowski; Youfu Li; Marc R Barnard; Marsha L Fox; Matthew D Linden; Atsuhiro Sugidachi; Kenneth J Winters; Mark I Furman; Alan D Michelson
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Chad E Darling; Patrick B Solari; Craig S Smith; Mark I Furman; Karin Przyklenk
'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Furman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Andrew L Frelinger; Joseph A Jakubowski; Youfu Li; Marc R Barnard; Matthew D Linden; I Tarnow; Marsha L Fox; Atsuhiro Sugidachi; Kenneth J Winters; Mark I Furman; Alan D Michelson
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Journal of thrombosis and haemostasis : JTH 2008;6(2):359-65.
2007: Andrew L Frelinger; Joseph A Jakubowski; Youfu Li; Marc R Barnard; Marsha L Fox; Matthew D Linden; Atsuhiro Sugidachi; Kenneth J Winters; Mark I Furman; Alan D Michelson
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Thrombosis and haemostasis 2007;98(1):192-200.
2007: Chad E Darling; Patrick B Solari; Craig S Smith; Mark I Furman; Karin Przyklenk
'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection.
Basic research in cardiology 2007;102(3):274-8.
2007: Matthew D Linden; Mark I Furman; Andrew L Frelinger; Marsha L Fox; Marc R Barnard; Youfu Li; Karin Przyklenk; Alan D Michelson
Indices of platelet activation and the stability of coronary artery disease.
Journal of thrombosis and haemostasis : JTH 2007;5(4):761-5.
2007: Paul Harrison; Andrew L Frelinger; Mark I Furman; Alan D Michelson
Measuring antiplatelet drug effects in the laboratory.
Thrombosis research 2007;120(3):323-36.
2007: Alan D Michelson; Matthew D Linden; Mark I Furman; Youfu Li; Marc R Barnard; Marsha L Fox; Wei C Lau; Thomas J McLaughlin; Andrew L Frelinger
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'.
Journal of thrombosis and haemostasis : JTH 2007;5(1):75-81.
2006: Alan D Michelson; Andrew L Frelinger; Mark I Furman
Current options in platelet function testing.
The American journal of cardiology 2006;98(10A):4N-10N.
2006: Andrew L Frelinger; Mark I Furman; Matthew D Linden; Youfu Li; Marsha L Fox; Marc R Barnard; Alan D Michelson
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Circulation 2006;113(25):2888-96.
2005: Marc R Barnard; Matthew D Linden; Andrew L Frelinger; Youfu Li; Marsha L Fox; Mark I Furman; Alan D Michelson
Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity.
Journal of thrombosis and haemostasis : JTH 2005;3(11):2563-70.
2005: Mark I Furman; Lori A Krueger; Matthew D Linden; Marsha L Fox; Steven P Ball; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Journal of thrombosis and haemostasis : JTH 2005;3(2):312-20.
2004: Matthew D Linden; Andrew L Frelinger; Marc R Barnard; Karin Przyklenk; Mark I Furman; Alan D Michelson
Application of flow cytometry to platelet disorders.
Seminars in thrombosis and hemostasis 2004;30(5):501-11.
2004: Michael R Tamberella; Mark I Furman
The role of platelet inhibition in the drug-eluting stent era.
Coronary artery disease 2004;15(6):327-9.
2004: Mark I Furman; Andrew L Frelinger; Alan D Michelson
GPIIb/IIIa inhibitor-induced dethrombosis.
Journal of thrombosis and thrombolysis 2004;18(1):11-7.
2004: Mark I Furman; Lori A Krueger; Matthew D Linden; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Journal of the American College of Cardiology 2004;43(12):2319-25.
2004: Mark I Furman; Joel M Gore; Frederick A Anderson; Andrzej Budaj; Shaun G Goodman; Alvaro Avezum; José López-Sendón; Werner Klein; Debabrata Mukherjee; Kim A Eagle; Omar H Dabbous; Robert J Goldberg
Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE).
American heart journal 2004;147(1):42-8.
2003: Andrew L Frelinger; Mark I Furman; Marc R Barnard; Lori A Krueger; Michael W Dae; Alan D Michelson
Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
The American journal of cardiology 2003;92(9):1099-101.
2003: David J Moliterno; James Hermiller; Dean J Kereiakes; Eric Yow; Robert J Applegate; Gregory A Braden; Eric J Dippel; Mark I Furman; Cindy L Grines; Neal S Kleiman; Glenn N Levine; Tift Mann; Ravi N Nair; Ronald A Stine; Steven J Yacubov; James E Tcheng
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study.
Journal of the American College of Cardiology 2003;42(6):1132-9.
2003: Marc R Barnard; Lori A Krueger; Andrew L Frelinger; Mark I Furman; Alan D Michelson
Whole blood analysis of leukocyte-platelet aggregates.
Current protocols in cytometry / editorial board, J. Paul Robinson, managing editor ... [et al.] 2003;Chapter 6():Unit 6.15.
2003: Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
American heart journal 2003;145(2):e6.
2003: R Brannon Claytor; Alan D Michelson; Jian-Ming Li; Andrew L Frelinger; Michael J Rohrer; Charles S C Garnette; Marc R Barnard; Lori A Krueger; Mark I Furman
The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin.
Journal of vascular surgery 2003;37(2):440-5.
2002: Michael J Rohrer; R Brannon Claytor; Charles S C Garnette; Craig C Powell; Marc R Barnard; Mark I Furman; Alan D Michelson
Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux.
Cardiovascular surgery (London, England) 2002;10(5):464-9.
2002: Stanley J Marciniak; Mary Ann Mascelli; Mark I Furman; Alan D Michelson; Joseph A Jakubowski; Robert E Jordan; Peter J Marchese; Andrew L Frelinger
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Thrombosis and haemostasis 2002;87(6):1020-5.
2002: Guy L Wheeler; Gregory A Braden; Steven R Steinhubl; Dean J Kereiakes; Kandice Kottke-Marchant; Alan D Michelson; Mark I Furman; Michele N Mueller; David J Moliterno; David C Sane
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
American heart journal 2002;143(4):602-11.
2002: Lori A Krueger; Marc R Barnard; Andrew L Frelinger; Mark I Furman; Alan D Michelson
Immunophenotypic analysis of platelets.
Current protocols in cytometry / editorial board, J. Paul Robinson, managing editor ... [et al.] 2002;Chapter 6():Unit 6.10.
2001: Mark I Furman; Dean J Kereiakes; Lori A Krueger; Michele N Mueller; K Pieper; Thomas M Broderick; John F Schneider; Wendy L Howard; Marsha L Fox; Marc R Barnard; Andrew L Frelinger; Alan D Michelson
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
American heart journal 2001;142(5):790-8.
2001: Mark I Furman; Marc R Barnard; Lori A Krueger; Marsha L Fox; E A Shilale; Darleen Lessard; P Marchese; Andrew L Frelinger; R J Goldberg; Alan D Michelson
Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction.
Journal of the American College of Cardiology 2001;38(4):1002-6.
2001: Alan D Michelson; Marc R Barnard; Lori A Krueger; C R Valeri; Mark I Furman
Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction.
Circulation 2001;104(13):1533-7.
2001: Andrew L Frelinger; Mark I Furman; Lori A Krueger; Marc R Barnard; Alan D Michelson
Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Circulation 2001;104(12):1374-9.
2001: Mark I Furman; Harold L Dauerman; RJ Goldberg; Jorge Yarzebski; Darleen Lessard; Joel M Gore
Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective.
Journal of the American College of Cardiology 2001;37(6):1571-80.
2001: R Brannon Claytor; Jian-Ming Li; Mark I Furman; Charles S C Garnette; Michael J Rohrer; Marc R Barnard; Lori A Krueger; Andrew L Frelinger; Alan D Michelson
Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion.
Cytometry 2001;43(4):308-13.
2000: Mark I Furman; P Nurden; M C Berndt; A T Nurden; SE Benoit; Marc R Barnard; Frederick A Ofosu; Alan D Michelson
The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system.
Thrombosis and haemostasis 2000;84(5):897-903.
2000: Mark I Furman; Lori A Krueger; Andrew L Frelinger; Marc R Barnard; Mary Ann Mascelli; Marian T Nakada; Alan D Michelson
GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
Thrombosis and haemostasis 2000;84(3):492-8.
2000: Mark I Furman; A L Frelinger III; Alan D Michelson
Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.
Current cardiology reports 2000;2(5):386-94.
2000: Alan D Michelson; Marc R Barnard; Lori A Krueger; Andrew L Frelinger; Mark I Furman
Evaluation of platelet function by flow cytometry.
Methods (San Diego, Calif.) 2000;21(3):259-70.
1999: Craig C Powell; Michael J Rohrer; Marc R Barnard; BD Peyton; Mark I Furman; Alan D Michelson
Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation.
Journal of vascular surgery 1999;30(5):844-51.
1998: BD Peyton; Michael J Rohrer; Mark I Furman; Marc R Barnard; L J Rodino; SE Benoit; Herbert B Hechtman; C R Valeri; Alan D Michelson
Patients with venous stasis ulceration have increased monocyte-platelet aggregation.
Journal of vascular surgery 1998;27(6):1109-15; discussion 1115-6.
1998: Mark I Furman; L Liu; SE Benoit; RC Becker; Marc R Barnard; Alan D Michelson
The cleaved peptide of the thrombin receptor is a strong platelet agonist.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(6):3082-7.
1998: Mark I Furman; SE Benoit; Marc R Barnard; C R Valeri; M L Borbone; RC Becker; Herbert B Hechtman; Alan D Michelson
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.
Journal of the American College of Cardiology 1998;31(2):352-8.
1996: Alan D Michelson; SE Benoit; Mark I Furman; W L Breckwoldt; Michael J Rohrer; Marc R Barnard; Joseph Loscalzo
Effects of nitric oxide/EDRF on platelet surface glycoproteins.
The American journal of physiology 1996;270(5 Pt 2):H1640-8.
1996: Alan D Michelson; SE Benoit; Mark I Furman; Marc R Barnard; P Nurden; A T Nurden
The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system.
Blood 1996;87(4):1396-408.